Immunome, Inc.
IMNM
$19.37
$2.2813.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.40% | -4.22% | 48.11% | -70.38% | -30.39% |
| Total Depreciation and Amortization | 1.81% | -0.83% | 22.02% | 4.20% | -15.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.85% | 3.03% | -84.88% | 219.07% | 10.21% |
| Change in Net Operating Assets | 187.89% | 30.95% | -421.97% | 136.39% | -21.92% |
| Cash from Operations | 18.00% | 6.89% | -26.14% | -23.10% | -46.03% |
| Capital Expenditure | -23.31% | 75.31% | -225.49% | 26.84% | 34.34% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 297.58% | -822.71% | -19.57% | -57.55% | 132.31% |
| Cash from Investing | 293.05% | -1,360.97% | -47.85% | -59.51% | 129.50% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 21,438.60% | -99.88% | 743.12% | 3,924.56% | -56.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -240.37% | 97.42% | -2,521.25% | -96.08% | 56.50% |
| Cash from Financing | 82,625.45% | -100.03% | 707.71% | 6,485.25% | -56.05% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 213.32% | -199.44% | 1,035.27% | -25.12% | 90.65% |